These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 25868705)

  • 1. Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis--an observational study.
    Rommer PS; Buckow K; Ellenberger D; Friede T; Pitschnau-Michel D; Fuge J; Stüve O; Zettl UK;
    Eur J Clin Invest; 2015 Jun; 45(6):587-93. PubMed ID: 25868705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    J Neurol; 2019 Nov; 266(11):2672-2677. PubMed ID: 31312958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
    Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
    Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis.
    Prosperini L; Fanelli F; Pozzilli C
    J Neurol Sci; 2016 May; 364():145-7. PubMed ID: 27084235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
    Lublin FD; Cutter G; Giovannoni G; Pace A; Campbell NR; Belachew S
    Mult Scler Relat Disord; 2014 Nov; 3(6):705-11. PubMed ID: 25891549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
    Dekker I; Leurs CE; Hagens MHJ; van Kempen ZLE; Kleerekooper I; Lissenberg-Witte BI; Barkhof F; Uitdehaag BMJ; Balk LJ; Wattjes MP; Killestein J
    Mult Scler Relat Disord; 2019 Aug; 33():82-87. PubMed ID: 31174043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
    Vukusic S; Durand-Dubief F; Benoit A; Marignier R; Frangoulis B; Confavreux C
    Mult Scler; 2015 Jun; 21(7):953-5. PubMed ID: 25305253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).
    Wiendl H; Butzkueven H; Kappos L; Trojano M; Pellegrini F; Paes D; Zhang A; Belachew S;
    PLoS One; 2016; 11(1):e0144834. PubMed ID: 26771747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and radiological control of highly active relapsing-remitting multiple sclerosis with first-line natalizumab.
    Meca-Lallana JE; Carreón-Guarnizo E; Hernández-Clares R; García-Molina E; Díaz-Pérez J; Leon-Hernández A; Zamarro-Parra J; Martín-Fernández JJ
    Neurodegener Dis Manag; 2017 Jun; 7(3):175-181. PubMed ID: 28592169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
    J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
    Kallweit U; Jelcic I; Braun N; Fischer H; Zörner B; Schreiner B; Sokolov AA; Martin R; Weller M; Linnebank M
    Clin Neuropharmacol; 2012; 35(2):77-80. PubMed ID: 22318192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.
    Barroso B; Miquel M; Marasescu R; Demasles S; Krim E; Bonnan M
    Mult Scler Relat Disord; 2015 Jul; 4(4):380-2. PubMed ID: 26195060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M; Schiavetti I; De Mercanti SF; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Ghezzi A; Bianchi A; Salemi G; Realmuto S; Sola P; Vitetta F; Cavalla P; Paolicelli D; Trojano M; Sormani MP; Durelli L
    JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.